Gascón, M.; Isla, D.; Cruellas, M.; Gálvez, E.M.; Lastra, R.; Ocáriz, M.; Paño, J.R.; RamÃrez, A.; Sesma, A.; Torres-Ramón, I.;
et al. Intratumoral versus Circulating Lymphoid Cells as Predictive Biomarkers in Lung Cancer Patients Treated with Immune Checkpoint Inhibitors: Is the Easiest Path the Best One? Cells 2020, 9, 1525.
https://doi.org/10.3390/cells9061525
AMA Style
Gascón M, Isla D, Cruellas M, Gálvez EM, Lastra R, Ocáriz M, Paño JR, RamÃrez A, Sesma A, Torres-Ramón I,
et al. Intratumoral versus Circulating Lymphoid Cells as Predictive Biomarkers in Lung Cancer Patients Treated with Immune Checkpoint Inhibitors: Is the Easiest Path the Best One? Cells. 2020; 9(6):1525.
https://doi.org/10.3390/cells9061525
Chicago/Turabian Style
Gascón, Marta, Dolores Isla, Mara Cruellas, Eva M. Gálvez, Rodrigo Lastra, Maitane Ocáriz, José Ramón Paño, Ariel RamÃrez, Andrea Sesma, Irene Torres-Ramón,
and et al. 2020. "Intratumoral versus Circulating Lymphoid Cells as Predictive Biomarkers in Lung Cancer Patients Treated with Immune Checkpoint Inhibitors: Is the Easiest Path the Best One?" Cells 9, no. 6: 1525.
https://doi.org/10.3390/cells9061525
APA Style
Gascón, M., Isla, D., Cruellas, M., Gálvez, E. M., Lastra, R., Ocáriz, M., Paño, J. R., RamÃrez, A., Sesma, A., Torres-Ramón, I., Yubero, A., Pardo, J., & MartÃnez-Lostao, L.
(2020). Intratumoral versus Circulating Lymphoid Cells as Predictive Biomarkers in Lung Cancer Patients Treated with Immune Checkpoint Inhibitors: Is the Easiest Path the Best One? Cells, 9(6), 1525.
https://doi.org/10.3390/cells9061525
